Published in Dermatol Ther (Heidelb) on March 17, 2012
Moderate to Severe Plaque Psoriasis With Scalp Involvement | NCT00791765
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb) (2012) 0.77
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40
Risk of myocardial infarction in patients with psoriasis. JAMA (2006) 9.42
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Sequential therapies for proliferative lupus nephritis. N Engl J Med (2004) 5.96
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med (2007) 5.39
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2005) 5.31
Polypharmacy in elderly patients. Am J Geriatr Pharmacother (2007) 5.06
Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med (1990) 3.99
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol (2007) 2.85
Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol (2006) 2.80
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol (2005) 2.17
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum (2005) 2.14
Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res (2005) 2.06
Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum (2006) 1.99
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.95
Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med (2006) 1.82
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 1.54
The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch Dermatol (1994) 1.53
Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol (2005) 1.53
The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol (2006) 1.50
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol (2009) 1.45
Treatment of psoriasis with azathioprine. Br Med J (1974) 1.34
Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum (2007) 1.25
Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology (2008) 1.22
[Cardiovascular risk factors. Insights from Framingham Heart Study]. Rev Esp Cardiol (2008) 1.15
Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol (2006) 1.14
Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J (2008) 1.10
Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med (2008) 1.10
Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol (2008) 1.09
Psoriatic nails: a prospective clinical study. J Cutan Med Surg (2003) 1.07
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol (2011) 1.06
Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol (1992) 1.05
Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol (2009) 1.00
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol (2011) 1.00
Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta (2005) 0.99
Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. Arthritis Rheum (2005) 0.95
Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology (2008) 0.95
Therapies for psoriatic nail disease. A systematic review. J Rheumatol (2006) 0.94
Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol (1997) 0.92
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol (2006) 0.91
Psoriatic onycho-pachydermo periostitis: treatment with methotrexate. Br J Dermatol (2000) 0.90
Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2008) 0.90
The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc (2004) 0.89
Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf (2008) 0.89
Scalp psoriasis, clinical presentations and therapeutic management. Dermatology (1998) 0.88
Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther (2006) 0.86
Widespread cutaneous carcinomas associated with human papillomaviruses 5, 14 and 20 after introduction of methotrexate in two long-term PUVA-treated patients. Dermatology (2001) 0.86
Methotrexate for psoriasis. Clin Exp Dermatol (1996) 0.86
Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol (2006) 0.86
Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol (2007) 0.85
Patients' perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol (2008) 0.84
Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol (1995) 0.83
The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Acta Derm Venereol Suppl (Stockh) (1996) 0.82
The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta Clin Belg (2007) 0.82
An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. J Am Acad Dermatol (2008) 0.81
Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum (1997) 0.81
Psoriatic onycho-pachydermo-periostitis successfully treated with low-dose methotrexate. Med Sci Monit (2006) 0.81
Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial. J Cutan Med Surg (2005) 0.80
Human papillomavirus in cutaneous squamous cell carcinoma and cervix of a patient with psoriasis and extensive ultraviolet radiation exposure. J Am Acad Dermatol (2001) 0.80
Is human papillomavirus type 5 the putative autoantigen involved in psoriasis? J Invest Dermatol (1998) 0.80
Retinoids for preventing the progression of cervical intra-epithelial neoplasia. Cochrane Database Syst Rev (2007) 0.78
Pustular psoriasis associated with hydroxychloroquine. J Am Acad Dermatol (1987) 0.78
Effective treatment of scalp psoriasis using the excimer (308 nm) laser. Photodermatol Photoimmunol Photomed (2006) 0.78
Safety and efficacy of alefacept in elderly patients and other special populations. J Drugs Dermatol (2005) 0.78
Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. Drugs Aging (2002) 0.78
Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg (2004) 0.77
Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol (1988) 0.77
Hydroxychloroquine provocation of psoriasis. J Rheumatol (1985) 0.76
Hydroxychloroquine in psoriasis: is it really harmful? Acta Derm Venereol (2006) 0.76
Azathioprine in psoriasis. Proc R Soc Med (1973) 0.76
Successful treatment of psoriatic nails with low-dose cyclosporine administration. Eur J Dermatol (2007) 0.76
Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin Dermatol (2006) 0.76
An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use. Ann Rheum Dis (2000) 0.76
Cyclosporin pharmacokinetics in the elderly. Drugs Aging (1999) 0.76
Psoriasis of the scalp treated with Grenz rays or topical corticosteroid combined with Grenz rays. A comparative randomized trial. Br J Dermatol (1988) 0.76
Additional effect of grenz rays on psoriasis lesions of the scalp treated with topical corticosteroids. Dermatologica (1987) 0.76
Dermatological drug dosage in the elderly. Skin Therapy Lett (2006) 0.76
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet (2006) 9.56
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol (2008) 3.95
Effectiveness of multifaceted educational programme to reduce antibiotic dispensing in primary care: practice based randomised controlled trial. BMJ (2012) 3.44
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol (2004) 2.96
Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet (2010) 2.76
Early pottery at 20,000 years ago in Xianrendong Cave, China. Science (2012) 2.73
Cinacalcet for the treatment of calciphylaxis. Arch Dermatol (2007) 2.57
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum (2009) 2.49
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis (2012) 2.29
National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol (2007) 2.29
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol (2005) 2.28
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26
Training practitioners to deliver opportunistic multiple behaviour change counselling in primary care: a cluster randomised trial. BMJ (2013) 2.22
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol (2009) 2.21
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol (2008) 2.19
Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol (2012) 2.19
Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol (2005) 2.15
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res (Hoboken) (2014) 2.09
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol (2004) 2.07
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol (2009) 1.94
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol (2009) 1.88
Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. J Invest Dermatol (2009) 1.82
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol (2008) 1.81
Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol (2010) 1.80
Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat (2009) 1.80
A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol (2003) 1.77
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. Biol Psychiatry (2008) 1.69
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod. Int J Dermatol (2004) 1.59
Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet (2009) 1.58
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol (2006) 1.54
AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol (2008) 1.54
Mammalian homolog of Drosophila tumor suppressor lethal (2) giant larvae interacts with basolateral exocytic machinery in Madin-Darby canine kidney cells. Mol Biol Cell (2002) 1.54
Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol (2002) 1.54
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.53
Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1. Dev Med Child Neurol (2012) 1.53
Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol (2013) 1.52
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
New viral vaccines for dermatologic disease. J Am Acad Dermatol (2008) 1.50
Aggression: the testosterone-serotonin link. Isr Med Assoc J (2003) 1.49
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol (2009) 1.48
Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol (2008) 1.48
Group-based cognitive-behavioural anger management for people with mild to moderate intellectual disabilities: cluster randomised controlled trial. Br J Psychiatry (2013) 1.45
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol (2009) 1.45
The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol (2008) 1.45
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol (2008) 1.43
Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol (2012) 1.43
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol (2005) 1.41
Small volume albumin administration protects against hemorrhagic shock-induced bone marrow dysfunction. J Trauma (2004) 1.40
National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol (2008) 1.40
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
Parvovirus B19-associated systemic lupus erythematosus: clinical mimicry or autoimmune induction? J Rheumatol (2010) 1.39
Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol (2003) 1.37
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol (2004) 1.36